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 The present study aimed to investigate the role of 
polymorphisms of the dopamine receptors and transporters genes 
(DRD1, DRD2, SLC6A3) in the pathogenesis of antipsychotic-
induced HP in patients with schizophrenia. 
 431 Russian patients with schizophrenia were examined. The 
average age of these patients was 42.1±1.4 years.  
 
 Serum prolactin (PRL) levels were measured using AccuBind 
ELISA Microwells kit (Monobind Inc., USA)). The upper limits for 
normal PRL concentration were set at ≤20 ng/ml for men and ≤25 
ng/ml for non-pregnant, non-nursing women. 
 
 Genotyping was carried out of 17 polymorphic variants of the 
dopamine receptors genes DRD1, DRD2 and dopamine 
transporter gene SLC6A3, with the use of MassARRAY® Analyzer 
4 (Agena Bioscience™).  
 
 SPSS software was used for statistical analysis. The Hardy-
Weinberg equilibrium (HWE) of genotypic frequencies was tested 
by the chi-square test. 
 All patients with schizophrenia were divided into two 
groups: those with and without HP. Patients from both groups were 
genotyped for DRD1 variants: rs4532, rs936461; for DRD2 
variants: rs4245147, rs6279, rs2734842 and for SLC6A3 variants: 
rs3756450, rs2550956, rs6347, rs2617605, rs3863145, rs250686, 
rs464049, rs4975646, rs1048953, rs11133767, rs27048, rs40184. 
   Statistically significant result was obtained for 
polymorphic variant rs2550956 of the gene SLC6A3 (χ2 = 9,992; p 
= 0,007), which suggests its involvement in the development of HP.  
The heterozygous genotype TC of rs2550956 was significantly less 
common in patients with elevated levels of prolactin and it 































 Table 1 – Distribution of genotypes and alleles of 
polymorphic variant rs2550956 of the gene SLC6A3 between 
patients with and without hyperprolactinemia (HP) 
 Our results indicate that genetic variants of SLC6A3 is 
associated with functional consequences on the modulation of 
prolactin secretion. Neurotransmitter systems are involved in the 
mechanisms of action of antipsychotic drugs; therefore, a further 
search for genetic markers associated with the development of side 
effects of antipsychotic therapy is needed, that will contribute to the 
development of effective methods of diagnosis, correction and 
treatment of schizophrenia, as well as of compliance of patients with 
mental disorders to psychotropic therapy. 
O B J E C T I V E  
B A C K G R O U N D  
M E T H O D S  
C O N C L U S I O N  
R E S U LT S  
 Long-term antipsychotic drug usage is the cornerstone of 
schizophrenia treatment. Antipsychotic drugs not only control 
symptoms by affecting dopaminergic neurotransmission, but also 
cause side effects including hyperprolactinemia. Prolactin 
secretion is persistently inhibited by dopamine, and antipsychotic 
drugs are believed to increase prolactin release by blocking 
dopamine receptors in the pituitary gland.  
 Genes coding for dopamine receptors and transporters 
are considered as candidate genes responsible for the 
antipsychotic-induced hyperprolactinemia (HP). 
